PI-1840

• UNSPSC Description:

  PI-1840 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α[1][2].

• Target Antigen:

  Apoptosis; Autophagy; Bcl-2 Family; Caspase; NF-κB; PARP; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease;NF-κB

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PI-1840.html

• Purity:

  98.78

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

• Smiles:

  O=C(N(C(C)C)CC1=NC(C2=CC=CN=C2)=NO1)COC3=CC=C(CCC)C=C3

• Molecular Weight:

  394.47

• References & Citations:

  [1]Kazi A, et, al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014 Apr 25;289(17):11906-11915.|[2]Chen Y, et, al. Non covalent proteasome inhibitor PI 1840 induces apoptosis and autophagy in osteosarcoma cells. Oncol Rep. 2019 May;41(5):2803-2817.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1401223-22-0